Hunan Provincial Key Laboratory of Emergency and Critical Care Metabonomics, Institute of Emergency Medicine, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan, China.
Department of Emergency, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, Hunan, China.
Sci Rep. 2024 Jan 10;14(1):963. doi: 10.1038/s41598-023-50696-y.
The Hedyotis diffusa-Scutellaria officinalis pair (HD-SB) has therapeutic effects on a variety of cancers. Our study was to explore the mechanism of HD-SB in the treatment of hepatocellular carcinoma (HCC). A total of 217 active ingredients of HD-SB and 1196 HCC-related targets were reserved from the TCMSP and the SwissTarget Prediction database, and we got 63 intersection targets from GeneCards. We used a Venn diagram, and Cytoscape found that the three core ingredients were quercetin, luteolin, and baicalein. The PPI analysis showed that the core targets were TP53, CDK2, XPO1, and APP. Molecular docking results showed that these core ingredients had good binding potential with the core targets. HD-SB acts simultaneously on various HCC-related signaling pathways, including proteoglycans in cancer and the P53 signaling pathway. In vitro experiments confirmed that HD-SB can inhibit HepG2 cell proliferation by increasing TP53 and APP levels and decreasing XPO1 and CDK2 levels. This study analyzed active ingredients, core targets, and central mechanisms of HD-SB in the treatment of HCC. It reveals the role of HD-SB in targeting the P53 signaling pathway in the treatment of HCC. We hope that our research could provide a new perspective to the therapy of HCC and find new anticancer drugs.
鸡矢藤-黄芩对（HD-SB）对多种癌症具有治疗作用。本研究旨在探讨 HD-SB 治疗肝细胞癌（HCC）的作用机制。从 TCMSP 和 SwissTarget Prediction 数据库中保留了 HD-SB 的 217 种活性成分和 1196 种 HCC 相关靶点，并从 GeneCards 中获得了 63 个交集靶点。我们使用 Venn 图和 Cytoscape 发现了三个核心成分，分别是槲皮素、木樨草素和黄芩素。PPI 分析表明，核心靶点是 TP53、CDK2、XPO1 和 APP。分子对接结果表明，这些核心成分与核心靶点具有良好的结合潜力。HD-SB 同时作用于多种 HCC 相关信号通路，包括癌症中的蛋白聚糖和 P53 信号通路。体外实验证实，HD-SB 通过增加 TP53 和 APP 水平，降低 XPO1 和 CDK2 水平，抑制 HepG2 细胞增殖。本研究分析了 HD-SB 治疗 HCC 的活性成分、核心靶点和中心机制。它揭示了 HD-SB 在靶向治疗 HCC 的 P53 信号通路中的作用。我们希望我们的研究能为 HCC 的治疗提供一个新的视角，并发现新的抗癌药物。
